Switching to the drug letrozole following 5 years of treatment with tamoxifen reduces the risk of hormone-dependent breast cancer recurrence, but not overall survival, among postmenopausal women, ...

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial This report ...

SAN ANTONIO (Reuters Health) - Letrozole is more effective than tamoxifen as an initial hormone therapy in postmenopausal women with hormone-sensitive, early breast cancer, researchers announced here ...

Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and ...

In the long term, the aromatase inhibitor letrozole is more effective at preventing the return of breast cancer and significantly improves survival time compared with tamoxifen in postmenopausal women ...

The study by Regan and colleagues presents an update on efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8.1 years median follow-up. BIG 1-98 is a randomized, phase 3, ...

Mar. 24 -- TUESDAY, March 11 (HealthDay News) -- There's good news for the 60 percent of women with breast cancer whose malignancies are estrogen-driven: Researchers say taking the aromatase inhibitor ...

For postmenopausal women with breast cancer, treatment with the drug letrozole (Femara) increases survival after surgery more than the widely used tamoxifen, a new study confirms. Both letrozole and ...

Dec. 10 -- A new class of breast cancer drugs shows promise in the treatment of breast cancer and may bring new hope to women with both early- and advanced-stage cancers. Two drugs — anastrazole and ...

Please provide your email address to receive an email when new articles are posted on . Use of an aromatase inhibitor instead of tamoxifen reduced the risk for breast cancer recurrence among ...

The Breast International Group (BIG) 1-98 study evaluated adjuvant endocrine therapy in postmenopausal women who had hormone receptor-positive early-stage breast cancer. The study participants were ...

Taking the breast cancer pill Femara can significantly reduce the chances that a woman's cancer will return, even long after she has stopped taking the estrogen blocker tamoxifen, U.S. researchers ...